SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Net Asset Value(s)

13 Jun 2022 07:00

RNS Number : 5602O
RTW Venture Fund Limited
13 June 2022
 

LEI: 549300Q7EXQQH6KF7Z84

13 June 2022

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 May 2022 (the "NAV") was US$258.3 million, or US$1.22 per ordinary share.

As at 31 May 2022, 33.7 per cent. of the total NAV was invested in privately-held core portfolio companies and 29.3 per cent. of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments.

For Further Information:

RTW Investments, LP

+1 (646) 343 9280

Stephanie Sirota, Chief Business Officer

 

Woody Stileman, Managing Director, Strategic Partnerships

 

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 May 2022. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPUUAQUPPGMP
Date   Source Headline
30th Apr 20257:00 amRNSJade Biosciences merges with Aerovate Therapeutics
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20251:30 pmRNSAnnual Financial Report
16th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:01 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Apr 202512:30 pmRNSDirector/PDMR Shareholding
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 202512:30 pmRNSNew Investment in AIRNA
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSAnnual Financial Report
28th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:01 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSMonthly Valuation Update and Factsheet
13th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSNotice of Annual Results
7th Mar 20257:00 amRNSTransaction in Own Shares
26th Feb 20257:00 amRNSRTW CIO increases position to 15%
25th Feb 20251:00 pmRNSMaterial purchase by CIO of the Investment Manager
17th Feb 20257:00 amRNSDirector/PDMR Shareholding
14th Feb 20257:00 amRNSMonthly Valuation Update and Factsheet
28th Jan 20257:00 amRNSMaterial Update from Portfolio Company
27th Jan 20257:00 amRNSKailera Reports Positive Data in Ph2 Obesity Trial
17th Jan 20257:01 amRNSNew Investment in Series A of Windward Bio
17th Jan 20257:00 amRNSAdditional Investment in Umoja Biopharma
15th Jan 20257:00 amRNSMonthly Valuation Update and Factsheet
14th Jan 20257:00 amRNSAdditional Investment in Numab Therapeutics
10th Jan 20257:00 amRNSNew Investment in Series A of Alesta Therapeutics
30th Dec 20247:00 amRNSCORXEL Announces Two Significant Transactions
20th Dec 202412:15 pmRNSNew Investment in Series A of Ottimo Pharma
13th Dec 20247:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 202412:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSAppointment of Senior Independent Director
15th Nov 20247:00 amRNSCORXEL Announces Acceptance of NDA for Aficamten
14th Nov 20247:00 amRNSMonthly Valuation Update and Factsheet
1st Nov 20242:00 pmRNSNew Investment in Series C Round of Evommune, Inc.
1st Nov 20247:00 amRNSRTW Biotech Opportunities’ 5th Anniversary
14th Oct 20246:12 pmRNSMonthly Valuation Update and Factsheet Replacement
14th Oct 20247:00 amRNSMonthly Valuation Update and Factsheet
3rd Oct 20247:00 amRNSLaunch of Obesity Company Kailera Therapeutics
2nd Oct 20247:00 amRNSNew Investment in Aktis Oncology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.